Australia Antigen in Chronic Hepatitis in Australia*

J. D. MATHEWS,† M.B., B.Sc., M.R.A.C.P.; I. R. MACKAY,‡ M.D., F.R.C.P., F.R.A.C.P.

British Medical Journal, 1970, 1, 259-261

Summary: Of 53 cases of active chronic liver disease two were found to be carriers of Australia antigen Au (1)—an elderly woman with typical lupoid hepatitis and an elderly mortuary attendant with serologically atypical active chronic hepatitis. Au (1) was detected also in the serum of 7 out of 20 patients with clinically atypical acute hepatitis—one was an elderly Italian woman, one had hepatitis in the puerperium, and five had a history of transfusion or inoculation. The antigen was not found in 20 typical cases of infectious hepatitis in young people in 86 patients with other diseases. Antibody to Au (1) was present in only 2 out of 102 patients who had received numerous transfusions.

We conclude, firstly, that Au (1) antigen is rare in white Australians (in keeping with the low incidence of serum hepatitis in Australia), and, secondly, that Au (1) positivity in hepatitis patients is associated with transfusions and with older age. We suggest that active chronic hepatitis and lupoid hepatitis may follow infection of susceptible individuals with Au (1)-positive hepatitis virus, but persistence of the virus in high titre does not appear to be necessary for chronicity of the disease.

Introduction

The Australia antigen Au (1) has been detected by immunoprecipitation (Blumberg *et al.*, 1965), particularly in serum from patients with serum hepatitis (Prince, 1968a, 1968b; Giles *et al.*, 1969; Turner and White, 1969) and also from some patients with acute infectious hepatitis (Blumberg *et al.*, 1967; London *et al.*, 1969), active chronic hepatitis (Fox *et al.*, 1969; Gitnick *et al.*, 1969; Wright *et al.*, 1969); and leukaemia and Down's syndrome (Blumberg *et al.*, 1968). Blood containing Au (1) antigen induces hepatitis when transfused (Gocke and Kavey, 1969), and Au (1)-positive sera contain virus-like particles which are agglutinated by anti-Au (1) serum (Bayer *et al.*, 1968; Hirschman *et al.*, 1969); thus Au (1) antigen is presumed to be a component of a virus which can cause acute hepatitis. Two serological types of hepatitis virus exist which differ in incubation period (Krugman *et al.*, 1967); serum from cases of long-incubation-period hepatitis is Au (1)-positive, whereas serum from cases of short-incubation-period hepatitis is Au (1)-negative (Giles *et al.*, 1969). The data of Prince (1968b) indicate that his serum hepatitis antigen is identical with the Au (1) antigen of Blumberg.

A major interest in this unit has been the study of active chronic hepatitis, and particularly the subgroup with multi-system disease and antinuclear antibodies—lupoid hepatitis. In view of suggestions that active chronic hepatitis is perpetuated by a hepatitis virus (Wright *et al.*, 1969), stored and

fresh sera from patients with lupoid hepatitis, active chronic hepatitis, and other hepatic and autoimmune diseases were tested for Au (1) antigen.

Methods

Reference sera with Au (1) activity and anti-Au (1) activity were obtained from London (Dr. Yvonne Cossart) and Philadelphia (Dr. B. Blumberg). One hundred and two sera were obtained from Melbourne hospital patients who had received numerous transfusions. Sera from patients with hepatic and autoimmune diseases were obtained from a bank within this unit. These specimens, collected during 1956-69, had been stored at -20°C ., but most had been occasionally thawed and refrozen. Where possible, three serum specimens were selected for each patient with a diagnosis of lupoid hepatitis (31 patients) or active chronic hepatitis (22 patients); the diagnostic criteria for these diseases were as described by Mackay *et al.*, (1965). The earliest and the latest available and a randomly selected third specimen were chosen. Subsequently additional sera were tested from any patients found to be Au (1)-positive (Table I, group A). One, two, or three recent specimens

TABLE I.—Prevalence of Au (1) Antigen

Group Surveyed	No. Tested		No. Positive		Per cent. Positive
	Patients	Sera	Patients	Sera	
A Active chronic liver disease ¹					
Lupoid hepatitis ..	31	97	1	14	3.8
Active chronic hepatitis ..	22	62	1	8	
B Suspected serum hepatitis ^{1,2,3,4}	11*	12	2*	2	18.2
C Sporadic hepatitis ^{1,2,5}	6	6	2	2	33.3
D Haemodialysis patients ²	10‡	29	3‡	7	30.0
E Haemodialysis unit staff ²	22	22	0	0	0
F Typical infectious hepatitis ⁶	20	20	0	0	0
G Other liver diseases ¹ †	34	51	0	0	0
H Other autoimmune disorders ¹	18	29	0	0	0
I Miscellaneous diseases ¹	34	35	0	0	0

Sources of sera: ¹Clinical Research Unit. ²Royal Melbourne Hospital. ³Blood Transfusion Centre, Perth, Western Australia. ⁴Dr. T. B. Reynolds, Los Angeles, U.S.A. (one case of transfusion hepatitis with evolution to cirrhosis*). ⁵Queen Victoria Hospital, Melbourne. ⁶Fairfield Infectious Diseases Hospital Victoria.

†Primary biliary cirrhosis. Alcoholic cirrhosis. Haemochromatosis. Cryptogenic cirrhosis. Wilson's disease.

‡Three had hepatitis.

of serum were selected from patients with other hepatic or autoimmune disorders, including a group of sera from patients with acute hepatitis after inoculation—"suspected serum hepatitis" (group B)—and a small group of adult and elderly patients with acute hepatitis from whom no definite history of inoculation or hepatitis contact was obtained (group C). Twenty-nine sera were collected from 10 patients receiving haemodialysis in the renal unit of this hospital (group D). Specially selected acute-phase sera from 20 children and young adults with typical infectious hepatitis were obtained from an infectious diseases hospital; most gave a history of hepatitis contact (group F).

*Publication No. 1375 from the Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

†Pathologist to the Clinical Research Unit.

‡Head of the Clinical Research Unit.

The Walter and Eliza Hall Institute of Medical Research and the Royal Melbourne Hospital, Melbourne.

Double diffusion was carried out in agarose gel prepared by the method of Prince (1968a). Microscope slides 2.5 by 7.5 cm. were coated with 2.5 ml. of gel. Serum samples were placed in holes, 3.5 mm. in diameter, punched in a hexagonal pattern with 7.2 mm. spacing. Slides were kept in a humid chamber at room temperature. Strongly reacting sera gave precipitin lines within 12 to 24 hours which increased in density up to 72 hours. Weaker reactions appeared after 24 to 48 hours. Reactions were read finally after seven days' incubation.

Results

Occurrence of Anti-Au (1) in Transfused Patients.—Of 102 sera from patients with numerous transfusions, two reacted with serum known to contain Au (1) antigen—one (Y) from a youth with haemophilia and one (Z) from a man with peptic ulcer, severe gastrointestinal bleeding and acute renal failure. Moreover, these test sera gave reactions of identity with the two reference anti-Au (1) sera. The potency of the local antiserum (Z) was tested by a chequerboard titration against the reference antigen provided by Dr. Blumberg. The two antisera were of the same potency; both gave visible precipitin lines at dilutions of 1:1 to 1:8, depending on the concentration of the test antigen. In subsequent tests antiserum Z was used (undiluted) for the detection of antigen.

Patients with Active Chronic and Lupoid Hepatitis.—Of the 53 patients (143 sera tested) with active chronic and lupoid hepatitis, two (six sera) were positive for Au (1) antigen. Sixteen additional specimens from these two patients were later tested and all were positive. One of these two was an elderly woman with typical lupoid hepatitis, and the other was a mortuary attendant with atypical active chronic hepatitis (see Table II and Appendix).

TABLE II.—Details of Patients with Positive Reactions for Au (1) Antigen

Group	Case No.	Sex	Age	Details	Location
A	1	F	71	Lupoid hepatitis 1961-9. (see Appendix, Case 1)	C.R.U.*
	2	M	55	Mortuary attendant. Active chronic hepatitis January 1966. (see Appendix, Case 2)	C.R.U.*
B	3	F	27	Blood transfusion June 1969. Hepatic encephalopathy August 1969. Recovered	Perth, W.A.
	4	M	65	Hepatitis in December 1965 following transfusion. Progression to cirrhosis. Persistence of Au (1) to 1969	Los Angeles, U.S.A.
C	5	F	61	Italian immigrant. Infectious hepatitis of slow onset June 1968. Recovery in six weeks with disappearance of Au (1)	C.R.U.*
	6	F	23	Hepatitis in puerperium July 1969. Hepatosplenomegaly	Melbourne
D	7	M	26	Hepatitis March 1969 with recovery and disappearance of antigen in May 1969	Melbourne
	8	F	26	Hepatitis July 1969 after detection of antigen in serum. Persistence of Au (1) and hepatitis for three months	Melbourne
	9	M	29	Mild hepatitis August 1969 with recovery and disappearance of antigen	Melbourne

*Clinical Research Unit.

Patients with Hepatitis of Various Types.—Two of 11 patients with "suspected serum hepatitis" (group B) gave positive reactions; one of these positive sera came from a patient

in Los Angeles who had developed cirrhosis following transfusion hepatitis. Of six patients with atypical acute hepatitis (group C) two gave positive reactions. Three of the 10 patients receiving haemodialysis developed hepatitis and Au (1) antigen was detected in the serum of all three; in one it was detected two weeks before the onset of hepatitis (group D). Antigen was not detected in serum from any of 22 members of staff of the haemodialysis unit (group E). None of the 20 sera from young patients with typical acute infectious hepatitis (group F) had Au (1) activity.

Other Hepatic and Autoimmune Diseases.—None of 80 sera from patients with a variety of other liver or autoimmune diseases was positive for Au (1) (see Table I).

Discussion

Australia antigen Au (1) was detected in the serum of one out of 31 cases of lupoid hepatitis (an elderly woman) and in one out of 22 other cases of active chronic hepatitis (an elderly mortuary attendant); this contrasts with prevalences of 10% and 24% of Au (1) positivity in cases of active chronic hepatitis in the U.S.A. (Gitnick *et al.*, 1969; Wright *et al.*, 1969). Of seven other patients in our study whose sera were positive for Au (1) antigen, five had a history compatible with serum hepatitis, three were patients with renal failure receiving haemodialysis, one was a patient who developed hepatic encephalopathy two months after a blood transfusion, and one patient whose serum was referred from Los Angeles developed cirrhosis after posttransfusion hepatitis. Two Au (1)-positive patients had no inoculation history: an Italian woman aged 61 with atypical acute hepatitis and an Australian woman aged 23 with hepatitis in the puerperium (see Table II). We failed to detect the antigen in a wide range of other hepatic and non-hepatic diseases, including 20 cases of typical acute infectious hepatitis in young people.

In Australia the Au (1) antigen is detected less often in association with acute and chronic hepatitis than it is in the eastern United States and Japan (Okochi and Murakami, 1968; Gocke and Kavey, 1969; Hirschman *et al.*, 1969; London *et al.*, 1969; Wright *et al.*, 1969). This is not attributable to differences in reagents or methods, as the antiserum used in our survey was comparable in sensitivity to that supplied by Dr. Blumberg. Moreover, the findings did not suggest that the antigen had disappeared from our stored sera. The relative rarity of Au (1) in Melbourne is further shown by the low prevalence (2%) of anti-Au (1) antibodies in sera from recipients of numerous blood transfusions. The prevalence of Au (1) antibody in Great Britain was even lower (Y. E. Cossart, personal communication, 1969). The Australian and British findings are in contrast to the higher prevalences of antibody (17-28%) in frequently transfused patients in the U.S.A. (Gocke and Kavey, 1969; Hirschman *et al.*, 1969), but they accord with the clinical experience that serum hepatitis is an uncommon disease in Australia and Great Britain (Cossart, 1969), where blood donors are volunteers.

Despite the regional variations in prevalence, the presence of Au (1) antigen in the serum of some patients with chronic hepatitis adds to the likelihood that viral hepatitis, occasionally at least, precedes and leads on to active chronic hepatitis and cirrhosis. We recall that 3 out of 25 patients with lupoid hepatitis and 4 out of 25 patients with active chronic hepatitis in this unit gave a definite history of hepatitis contact shortly before the onset of their illness (Mackay *et al.*, 1965); other evidence bearing on this was cited by Mackay (1968). On the other hand, viral hepatitis antigen Au (1), as detected by immunoprecipitation, occurred too infrequently in our study to be regarded as essential for the chronicity of active chronic hepatitis and lupoid hepatitis, the conclusion also reached in the London study of Fox *et al.* (1969).

The age incidence of Au (1) antigen in hepatitis is of interest. Each of the Au (1)-positive subjects in our present study who was a patient in this unit (Cases 1, 2, and 5, Table II) was over the age of 50. London *et al.* (1969) commented on the absence of Au (1) in young hepatitis patients in the U.S.A., and Gitnick *et al.* (1969) mentioned three patients with active chronic hepatitis who were positive for Au (1) but were men aged 75, 46, and 66 years; this age and sex distribution is unusual for active chronic hepatitis. A bimodal age distribution of 41 patients with lupoid hepatitis was described by Mackay (1968): most patients were girls or young women, but a proportion were males (17%) or older women (33%), and 40% were over the age of 40. We suggest that Au (1)-positive cases of chronic hepatitis come from a subpopulation of older patients, and that active chronic hepatitis in this presumably susceptible older age group is attributable to initial infection with or breakdown of immunological tolerance to Au (1)-positive (long-incubation-period) hepatitis virus. In younger individuals, however, active chronic hepatitis might follow infection with the short-incubation-period hepatitis virus (Au (1)-negative) which is not yet demonstrable serologically.

Appendix

Case 1.—A woman aged 63 in 1961 had symptoms of hepatitis for three weeks. The serum gammaglobulin rose to 4.7 g./100 ml. The test for L.E. cells was strongly positive. Liver biopsy showed active hepatitis with some distortion of architecture (Fig. 1).

FIG. 1.—Case 1. Liver biopsy showing "ballooned" and vacuolated liver cells, "rosettes," lobular invasion by fibroblasts, and portal reaction: active chronic hepatitis. (Haematoxylin and eosin. X 270.)

Prednisolone and later azathioprine induced pronounced improvement (Mackay and Wood, 1963; Case 22, Fig. 5). Liver biopsies in 1964 and 1968 showed quiescent active chronic hepatitis with prominence of plasma cells. Tests for smooth-muscle antibody were negative, for antinuclear factor positive but only to granulocyte nuclei, and for antimitochondrial antibody positive. All of 14 available serum specimens (from December 1965 to July 1969) contained Au (1) antigen.

Case 2.—A mortuary attendant aged 55 in 1966 presented with symptoms of hepatitis for 10 days. He had had jaundice five years previously. He had carried out a necropsy on a patient who had died from fulminant hepatitis two months earlier. The maximum

level of serum gammaglobulin was 2.4 g./100 ml. The liver biopsy was interpreted as active chronic hepatitis (Fig. 2). Prednisolone induced some but not full improvement. Tests for L.E. cells and

FIG. 2.—Case 2. Liver biopsy showing fibrosis with disruption of architecture, "piecemeal necrosis" in perlobular region, and moderate cellular reaction: active chronic hepatitis. (Haematoxylin and eosin. X 85.)

smooth-muscle antibody were negative and tests for antinuclear factor became weakly positive. Au (1) antigen was found in all eight specimens tested.

We thank Sir Macfarlane Burnet, Dr. Senga Whittingham, and Dr. I. J. Wood for their advice, and Dr. A. A. Ferris, Mr. J. Kaldor, Dr. R. Lucas, Professor R. A. Joske, Dr. L. Williams, Dr. M. Davey, and Dr. P. Kincaid-Smith for referring sera and providing details of diagnoses. Dr. T. B. Reynolds kindly allowed us to cite his case of posttransfusion cirrhosis. Dr. B. Blumberg and Dr. Y. Cossart provided reference antigens and antisera, and Dr. Blumberg's laboratory kindly confirmed the presence of Au (1) in our positive sera. Miss Jane Allardice provided valuable technical assistance. Both of us were supported by a grant from the National Health and Medical Research Council of Australia.

REFERENCES

- Bayer, M. E., Blumberg, B. S., and Werner, B. (1968). *Nature*, **218**, 1057.
 Blumberg, B. S., Alter, H. J., and Visnich, S. (1965). *Journal of the American Medical Association*, **191**, 541.
 Blumberg, B. S., Gerstley, B. J. S., Hungerford, D. A., London, W. T., and Sutnick, A. I. (1967). *Annals of Internal Medicine*, **66**, 924.
 Blumberg, B. S., Sutnick, A. I., and London, W. T. (1968). *Bulletin of the New York Academy of Medicine*, **44**, 1566.
 Cossart, Y. E. (1969). *Lancet*, **1**, 1216.
 Fox, R. A., Niazi, S. P., and Sherlock, S. (1969). *Lancet*, **2**, 609.
 Giles, J. P., McCollum, R. W., Berndtson, L. W., and Krugman, S. (1969). *New England Journal of Medicine*, **281**, 119.
 Gitnick, G. L., *et al.* (1969). *Lancet*, **2**, 285.
 Gocke, D. J., and Kavey, N. B. (1969). *Lancet*, **1**, 1055.
 Hirschman, R. J., Shulman, N. R., Barker, L. F., and Smith, K. O. (1969). *Journal of the American Medical Association*, **208**, 1667.
 Krugman, S., Giles, J. P., and Hammond, J. (1967). *Journal of the American Medical Association*, **200**, 365.
 London, W. T., Sutnick, A. I., and Blumberg, B. S. (1969). *Annals of Internal Medicine*, **70**, 55.
 Mackay, I. R. (1968). *Bulletin on Rheumatic Diseases*, **18**, 487.
 Mackay, I. R., Weiden, S., and Hasker, J. (1965). *Annals of the New York Academy of Sciences*, **124**, 767.
 Mackay, I. R., and Wood, I. J. (1963). *Gastroenterology*, **45**, 4.
 Okochi, K., and Murakami, S. (1968). *Vox Sanguinis*, **15**, 374.
 Prince, A. M. (1968a). *Proceedings of the National Academy of Sciences of the United States of America*, **60**, 814.
 Prince, A. M. (1968b). *Lancet*, **2**, 462.
 Turner, G. C., and White, G. B. B. (1969). *Lancet*, **2**, 121.
 Wright, R., McCollum, R. W., and Klatskin, G. (1969). *Lancet*, **2**, 117.